Mon11182019

Last updateSun, 21 Oct 2018 6pm

Cancer drug Gleevec could form the basis of a new class of drugs that block the development of brain-damaging plaques in Alzheimer's - Reuters (article link)

"Our findings reveal that gamma-secretase activating protein is a potential target for a new class of anti-amyloid therapies,"

- In prior work, Greengard discovered that Novartis AG's Gleevec or imatinib blocks gamma-secretase activating protein.
- The latest study, shows that this protein dramatically increases the production of beta amyloid, and blocking the protein in genetically engineered mice kept Alzheimer's brain plaques from developing.

"It's known that gamma-secretase not only makes beta amyloid, but it makes many other substances that are vital for the survival of our cells,"



Cancer drug points way to new Alzheimer's approach
http://www.reuters.com/article/idUSTRE6805J520100901

(Reuters) - An altered version of the cancer drug Gleevec could form the basis of a new class of drugs that block the development of brain-damaging plaques in Alzheimer's disease, U.S. researchers said on Wednesday.